FOXO4-DRI 10mg

All compounds and related materials are supplied as a complete research package and are provided strictly for laboratory research use only. This includes all necessary related materials (such as bacteriostatic water, syringes, and accessories) for research preparation. They are not intended for human or veterinary use, medical diagnosis, treatment, or any form of self-administration.

FoxO4-DRI 10 mg – Research Peptide for Senescent Cell Regulation and Cellular Longevity

FoxO4-DRI is a cell-penetrating peptide designed for the study of senescent cell apoptosis pathways and DNA repair regulation. In scientific research, FoxO4-DRI is investigated for its ability to modulate the interaction between FoxO4 and p53, a key mechanism involved in the survival of damaged or aging cells. Supplied as a lyophilized (freeze-dried) peptide for optimal stability and reproducibility in laboratory environments.

Historical Background and Scientific Context

FoxO4-DRI emerged from longevity and cancer biology research at Erasmus Medical Center in Rotterdam in the mid-2010s. Since its discovery, it has been used to explore targeted removal of senescent cells (“senolytic” activity) and restoration of tissue function in aged models. Between 2015 and 2025, preclinical investigations have focused on its molecular signaling effects related to p53 sequestration, mitochondrial resilience, and genomic protection — always within strictly controlled laboratory conditions.

Mechanistic Focus in Research

In laboratory models, FoxO4-DRI is studied for its interaction with the FoxO4 transcription factor and its role in cellular stress resistance: – Disruption of FoxO4-p53 binding to trigger apoptosis in senescent cells – Regulation of mitochondrial integrity and oxidative stress response – Modeling of DNA damage repair and longevity-related pathways – Comparative senolytic compound benchmarking

Analytical Verification (COA)

Laboratory: Liquilabs s.r.o., Czechia
Batch Number: GF082025009
Date Published: 12 October 2025
Identity (RT): 0.997 ± 0.005 confirmed by spectrum (998 ± 20)
Content: 10.57 mg ± 0.05 mg per vial
Purity: > 99.8 %
Bioburden: Not detected (USP <61>)
Endotoxin: < 0.001 EU/mg (USP <85>)
Heavy Metals: Not detected (As, Pb, Cd, Hg, Ni, V, Co)

Research Applications

– Senescent cell clearance and apoptosis modeling – p53-FoxO4 interaction and DNA repair studies – Mitochondrial stress and anti-oxidative signaling research – Longevity and regenerative biology investigations

Grail Formula Quality – From 24PEPTIDES

Every Grail Formula peptide is independently verified by Liquilabs for identity, purity, and analytical safety. Each batch is fully documented and traceable to ensure reproducibility in research. All compounds are supplied as lyophilized powders for long-term molecular stability.

When you choose Grail Formula FoxO4-DRI 10 mg…

…you receive a research-verified peptide with >99.8 % purity, confirmed identity, and full Liquilabs documentation. Delivered as a complete research package — everything included to begin your study immediately in a controlled environment.

⚠ Research Use Only

This compound and all related materials are intended solely for scientific and laboratory research. They are not approved for diagnostic or therapeutic use and must not be self-administered. Always handle with appropriate protective equipment and follow institutional safety protocols.

Verified FoxO4-DRI peptide (senolytic research compound)

COA verified by Liquilabs s.r.o. (Czechia)

Purity > 99.8 %, no microbial or heavy-metal contamination

Endotoxin < 0.001 EU/mg (USP )

Lyophilized (freeze-dried) for long-term stability

Delivered as a complete research package

For research use only

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.